Use of depot antipsychotic in patients in a psychosis clinic of a psychiatry hospital

2018 ◽  
Author(s):  
Alper Mert
Keyword(s):  
Depot Antipsychotic

Evaluation of Inpatient Depot Antipsychotic Prescribing

1996 ◽  
Vol 30 (12) ◽  
pp. 1381-1386 ◽  
Author(s):  
Dennis J Pabis ◽  
Peter G Dorson ◽  
M Lynn Crismon
Keyword(s):  
Length Of Stay ◽  
Product Information ◽  
Length Of Hospital Stay ◽  
Inpatient Setting ◽  
Pharmacy Staff ◽  
Antipsychotic Therapy ◽  
Fluphenazine Decanoate ◽  
Short Acting ◽  
Depot Antipsychotic ◽  
Depot Therapy

OBJECTIVE: To assess the use of fluphenazine decanoate and haloperidol decanoate in an inpatient setting. DESIGN: A prospective observational study conducted over a 3-month period. SETTING: A 400-bed state psychiatric hospital. INTERVENTIONS: The psychiatric pharmacy staff evaluated the medical records and new orders of 30 consecutive patients receiving depot antipsychotic formulations using a detailed evaluation form and the hospital pharmacy computer database. Criteria for evaluation were derived from the medical literature and product information, and included the following areas: diagnosis, stabilization on a short-acting form of the antipsychotic, appropriateness of dosage conversion to depot therapy, concomitant administration of short-acting antipsychotics (and duration of concomitant medications), and plasma concentration monitoring. RESULTS: Only 7 patients (23%) received what would be considered optimal depot antipsychotic therapy. These patients were receiving a stable dosage of a short-acting antipsychotic prior to conversion to depot therapy (i.e., ≥7 d), received optimal dose conversion to a depot form, and received optimum overlap with a short-acting preparation (i.e., overlap ≤7 d with fluphenazine HCl and 7–30 d with haloperidol HCl). When length of stay data were evaluated, no significant differences were observed in patients who received optimal therapy versus those who did not. There was also no difference in length of stay when the study group was compared with an age-, sex-, and diagnosis-matched cohort group. However, quantitatively fewer adverse effects were reported for patients whose treatment was considered optimal on the basis of the evaluation criteria. CONCLUSIONS: Depot antipsychotic therapy frequently did not meet the criteria for optimal use. This did not affect length of hospital stay in these individuals. However, individuals who met the criteria experienced quantitatively fewer adverse events.

Akathisia: Prevalence and Associated Dysphoria in an In-patient Population with Chronic Schizophrenia

1994 ◽  
Vol 164 (2) ◽  
pp. 177-183 ◽  
Author(s):  
Simon M. Halstead ◽  
Thomas R. E. Barnes ◽  
Jeremy C. Speller
Keyword(s):  
Tardive Dyskinesia ◽  
Negative Symptoms ◽  
Chronic Schizophrenia ◽  
Significant Relation ◽  
Orofacial Dyskinesia ◽  
Increased Risk ◽  
Depot Antipsychotic ◽  
Male Patients ◽  
Higher Doses ◽  
Dysphoric Mood

In a sample of 120 long-stay in-patients who fulfilled DSM–III–R criteria for schizophrenia, chronic akathisia and pseudoakathisia were relatively common, with prevalence figures of 24% and 18%, respectively. Compared with patients without evidence of chronic akathisia, those patients with the condition were significantly younger, were receiving significantly higher doses of antipsychotic medication, and were more likely to be receiving a depot antipsychotic. Patients who experienced the characteristic inner restlessness and compulsion to move of akathisia also reported marked symptoms of dysphoria, namely tension, panic, irritability and impatience. The findings support the suggestion that dysphoric mood is an important feature of akathisia. Male patients appeared to be at an increased risk of pseudoakathisia. No significant relation was found between chronic akathisia and tardive dyskinesia, although there was a trend for trunk and limb dyskinesia to be commonest in patients with chronic akathisia while orofacial dyskinesia was most frequently observed in those with pseudoakathisia. Akathisia may mask the movements of tardive dyskinesia in the lower limb. There was no evidence that akathisia was associated with positive or negative symptoms of schizophrenia nor with depression.

P-484 - The influence of depot antipsychotic treatment on the occurrence of MB. parkinsoni caused by medicaments- case report

2012 ◽  
Vol 27 ◽  
pp. 1
Author(s):  
Z. Golubovic ◽  
Z. Barac-Otasevic ◽  
A. Raznatovic ◽  
T. Perunovic-Jovanovic ◽  
V. Gazivoda ◽  
...  
Keyword(s):  
Case Report ◽  
Antipsychotic Treatment ◽  
Depot Antipsychotic

Depot Antipsychotics in the Prophylaxis of Bipolar Affective Disorder

1994 ◽  
Vol 165 (6) ◽  
pp. 827-829 ◽  
Author(s):  
R. Littlejohn ◽  
F. Leslie ◽  
J. Cookson
Keyword(s):  
Bipolar Disorder ◽  
British Journal ◽  
Affective Disorder ◽  
Antipsychotic Drugs ◽  
Prophylactic Treatment ◽  
Bipolar Affective Disorder ◽  
Manic Depressive ◽  
Depot Antipsychotic ◽  
Depot Antipsychotics ◽  
Depot Medication

BackgroundThe efficacy of depot antipsychotic drugs in the prophylaxis of bipolar affective disorder was investigated.MethodLife charts were constructed for 18 outpatients with bipolar disorder receiving prophylactic treatment with depot medication. The durations of affective episodes were compared during periods on or off medication.ResultsThe subjects suffered fewer relapses and spent significantly less time in hospital (P = 0.001) for treatment of manic, depressive and mixed affective illness during treatment with depot antipsychotics.ConclusionsDepot antipsychotic medication may be a useful prophylactic treatment for certain patients with bipolar affective disorder.British Journal of Psychiatry (1994), 165, 827–829

Compliance With Depot Antipsychotic Medication by Patients Attending Outpatient Clinics

1998 ◽  
Vol 49 (9) ◽  
pp. 1232-1234 ◽  
Author(s):  
Beth E. Heyscue ◽  
Gary M. Levin ◽  
Jacqueline P. Merrick
Keyword(s):  
Antipsychotic Medication ◽  
Outpatient Clinics ◽  
Depot Antipsychotic

Survey of Depot Antipsychotic Prescribing in Southern Adelaide

2005 ◽  
Vol 13 (3) ◽  
pp. 253-257 ◽  
Author(s):  
Peter Herriot ◽  
Kamran Kheirani
Keyword(s):  
Mental Health ◽  
Blood Glucose ◽  
Community Mental Health ◽  
Dose Reduction ◽  
Involuntary Movement ◽  
Dose Interval ◽  
Community Mental Health Service ◽  
The Past ◽  
Administration Interval ◽  
Depot Antipsychotic

Objective: Depot antipsychotic medication (DAP) is widely used in the treatment of schizophrenia and related disorders. The objectives of this study were to (i) determine whether DAP was being prescribed in accordance with established guidelines in terms of dose, interval of administration and indications; and (ii) assess the quality of the assessment and documentation of tardive dyskinesia (TD) as well as blood glucose and lipid abnormalities. Methods: The survey was carried out between April and June 2003 at all three public hospital affiliated community mental health centres located in the southern region of Adelaide. Data were extracted from three sources: depot prescription charts, community mental health service case notes and hospital case notes. Results: Two hundred and sixty-one patients were receiving DAP. The majority (89%) had a diagnosis of schizophrenia or schizoaffective disorder. The DAP prescribed most frequently was zuclopenthixol decanoate (57%) at a modal dose of 200 mg and a modal administration interval of 2weeks. Fifty-three per cent of patients had at least one dose reduction during the course of treatment. Four per cent of patients had a case note documented diagnosis of TD. Fifty-seven per cent of patients had at least one blood glucose test in the past year, with nearly half showing high results. Forty-seven per cent of patients had at least one lipid study in the past year, with more than half having high total cholesterol and 22% having high triglycerides. Conclusion: The results of this study indicate that DAP is being used mostly for the treatment of schizophrenia and related disorders, which is in agreement with established evidence-based guidelines. The finding of at least one documented attempt at DAP dose reduction or extension of interval of administration in approximately half of the patients receiving DAP is encouraging and may have an impact on reducing the likelihood of TD. A formal TD surveillance programme using a screening tool such as the Abnormal Involuntary Movement Scale is recommended. In addition, more frequent evaluation of blood glucose and lipid levels is needed.

Sign in / Sign up

Export Citation Format

Share Document